ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
First bronchiectasis patient dosed in Phase III trial to study brensocatib europeanpharmaceuticalreview
December 04, 2020The first patient with bronchiectasis has been dosed in the Phase III ASPEN study of brensocatib, a reversible inhibitor of dipeptidyl peptidase 1. -
EC Grants Authorization for ARIKAYCE Liposomal Nebulizer Dispersion for NTM Lung Infections americanpharmaceuticalreview
November 06, 2020Insmed Incorporated announced the European Commission (EC) has granted marketing authorization for ARIKAYCE? Liposomal 590 mg Nebulizer Dispersion for the treatment of nontuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium ...
Pharma Sources Insight January 2025
